CN104815166B - A kind of Chinese medicine composition for treating diabetes and its preparation and application - Google Patents
A kind of Chinese medicine composition for treating diabetes and its preparation and application Download PDFInfo
- Publication number
- CN104815166B CN104815166B CN201510243922.XA CN201510243922A CN104815166B CN 104815166 B CN104815166 B CN 104815166B CN 201510243922 A CN201510243922 A CN 201510243922A CN 104815166 B CN104815166 B CN 104815166B
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- chinese medicine
- medicine composition
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 65
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 14
- 241000209020 Cornus Species 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 241000605447 Anemarrhena Species 0.000 claims abstract description 8
- 229930191283 anemarrhena Natural products 0.000 claims abstract description 8
- 241000508269 Psidium Species 0.000 claims abstract description 7
- 241000237502 Ostreidae Species 0.000 claims abstract description 6
- 235000020636 oyster Nutrition 0.000 claims abstract description 6
- 241000202726 Bupleurum Species 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 21
- 239000000706 filtrate Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 9
- 239000012141 concentrate Substances 0.000 claims description 8
- 235000011399 aloe vera Nutrition 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 6
- 241000756122 Aristida purpurascens Species 0.000 claims description 5
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 244000292697 Polygonum aviculare Species 0.000 claims description 4
- 235000006386 Polygonum aviculare Nutrition 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 230000008020 evaporation Effects 0.000 claims description 4
- 229940107131 ginseng root Drugs 0.000 claims description 4
- 241001116389 Aloe Species 0.000 claims description 3
- 244000241838 Lycium barbarum Species 0.000 claims description 3
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 241000037740 Coptis chinensis Species 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 239000009636 Huang Qi Substances 0.000 claims 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims 2
- 241000405414 Rehmannia Species 0.000 claims 1
- 241000304195 Salvia miltiorrhiza Species 0.000 claims 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 9
- 235000008434 ginseng Nutrition 0.000 abstract description 9
- 235000007877 Diospyros australis Nutrition 0.000 abstract description 7
- 235000010875 Prunus nigra Nutrition 0.000 abstract description 7
- 235000018288 Vitex doniana Nutrition 0.000 abstract description 7
- 244000132619 red sage Species 0.000 abstract description 6
- 241001061264 Astragalus Species 0.000 abstract description 5
- 244000247747 Coptis groenlandica Species 0.000 abstract description 5
- 235000002991 Coptis groenlandica Nutrition 0.000 abstract description 5
- 235000017784 Mespilus germanica Nutrition 0.000 abstract description 5
- 235000000560 Mimusops elengi Nutrition 0.000 abstract description 5
- 244000236658 Paeonia lactiflora Species 0.000 abstract description 5
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract description 5
- 240000002577 Prunus nigra Species 0.000 abstract description 5
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 abstract description 5
- 235000007837 Vangueria infausta Nutrition 0.000 abstract description 5
- 235000006533 astragalus Nutrition 0.000 abstract description 5
- 230000007812 deficiency Effects 0.000 abstract description 5
- 229910052709 silver Inorganic materials 0.000 abstract description 5
- 239000004332 silver Substances 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 210000004233 talus Anatomy 0.000 abstract description 5
- 208000008454 Hyperhidrosis Diseases 0.000 abstract description 4
- 240000001341 Reynoutria japonica Species 0.000 abstract description 4
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract description 4
- 210000001124 body fluid Anatomy 0.000 abstract description 4
- 239000010839 body fluid Substances 0.000 abstract description 4
- 230000035900 sweating Effects 0.000 abstract description 4
- 206010010774 Constipation Diseases 0.000 abstract description 3
- 206010013954 Dysphoria Diseases 0.000 abstract description 3
- 206010037660 Pyrexia Diseases 0.000 abstract description 3
- 235000003642 hunger Nutrition 0.000 abstract description 3
- 230000002269 spontaneous effect Effects 0.000 abstract description 3
- 210000002700 urine Anatomy 0.000 abstract description 3
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 abstract description 2
- 206010043458 Thirst Diseases 0.000 abstract description 2
- 230000008030 elimination Effects 0.000 abstract description 2
- 238000003379 elimination reaction Methods 0.000 abstract description 2
- 239000012530 fluid Substances 0.000 abstract description 2
- 230000027939 micturition Effects 0.000 abstract description 2
- 230000036565 night sweats Effects 0.000 abstract description 2
- 206010029410 night sweats Diseases 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 2
- 244000182216 Mimusops elengi Species 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 235000000346 sugar Nutrition 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 240000004371 Panax ginseng Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 244000144927 Aloe barbadensis Species 0.000 description 4
- 235000002961 Aloe barbadensis Nutrition 0.000 description 4
- 240000002624 Mespilus germanica Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 239000010015 huanglian Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 244000109420 Vitex doniana Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical group COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001072909 Salvia Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- -1 Tween) Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种中药组合物,尤其涉及一种治疗糖尿病的中药组合物及其制备和应用,属于中医药领域。本发明的治疗糖尿病的中药组合物,其原料组成包括山萸肉、人参须、生地、黄精、黄芪、白芍、枸杞子、知母、元参、黄连、乌梅、番石榴皮、牡蛎、银柴胡、胡黄连、丹参、鬼箭羽、芦荟、虎杖。本发明的中药组合物益气养阴,清热生津。用于II型糖尿病燥热伤津兼气阴两虚证,症见口渴多饮,尿量频多,消谷善饥,形体渐瘦,倦怠乏力,自汗盗汗,五心烦热,尿浊,便秘等。The invention relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine composition for treating diabetes and its preparation and application, belonging to the field of traditional Chinese medicine. The traditional Chinese medicine composition for treating diabetes of the present invention, its raw material composition comprises cornus, ginseng, raw land, sealwort, astragalus, white peony root, medlar, anemarrhena, root ginseng, coptis, black plum, guava peel, oyster, silver Bupleurum, Huhuanglian, Danshen, Guijianyu, Aloe Vera, Polygonum cuspidatum. The traditional Chinese medicine composition of the invention nourishes qi and nourishes yin, clears away heat and promotes fluid production. It is used for type II diabetes with dryness, heat, body fluid and deficiency of both qi and yin. Symptoms include excessive thirst, frequent urination, elimination of grains and good hunger, gradual thinning, fatigue, spontaneous sweating, night sweats, dysphoria and fever, and turbid urine. Constipation etc.
Description
技术领域technical field
本发明涉及一种中药组合物,尤其涉及一种治疗糖尿病的中药组合物及其制备和应用,属于中医药领域。The invention relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine composition for treating diabetes and its preparation and application, belonging to the field of traditional Chinese medicine.
背景技术Background technique
糖尿病(diabetes)是一种以高血糖为特征的代谢性疾病,与高血压、高血脂一同称为“三高”,是由遗传因素、免疫功能紊乱、微生物感染及其毒素、自由基毒素、精神因素等各种致病因子作用于机体导致胰岛功能减退、胰岛素抵抗等而引发的糖、蛋白质、脂肪、水和电解质等一系列代谢紊乱综合征。特别是“成人型糖尿病”在四十岁以上的中年人染患率特别高。糖尿病时长期存在的高血糖,导致各种组织,特别是眼、肾、心脏、血管、神经的慢性损害、功能障碍。Diabetes (diabetes) is a metabolic disease characterized by hyperglycemia. Together with hypertension and hyperlipidemia, it is called the "three highs". Various pathogenic factors such as mental factors act on the body to cause a series of metabolic disorder syndromes such as sugar, protein, fat, water and electrolytes caused by hypofunction of pancreatic islets and insulin resistance. Especially "adult-onset diabetes" has a particularly high infection rate among middle-aged people over the age of forty. The long-term high blood sugar in diabetes leads to chronic damage and dysfunction of various tissues, especially the eyes, kidneys, heart, blood vessels, and nerves.
糖尿病分I型糖尿病、II型糖尿病、妊娠糖尿病及其他特殊类型的糖尿病。通常关注和研究较多的为I型糖尿病和II型糖尿病:Diabetes is divided into type I diabetes, type II diabetes, gestational diabetes and other special types of diabetes. Type I diabetes and type II diabetes are usually concerned and studied more:
①I型型糖尿病是一种自体免疫疾病。自体免疫疾病是由于身体的免疫系统对自身作出攻击而成的。糖尿病患者的免疫系统对自身分泌胰岛素的胰脏贝它细胞作出攻击并杀死他们,结果胰脏并不能分泌足够的胰岛素。因胰岛素分泌缺乏,患者需依赖外源性胰岛素补充以维持生命。① Type I diabetes is an autoimmune disease. Autoimmune diseases are caused by the body's immune system attacking itself. In diabetics, the immune system attacks and kills the beta cells of the pancreas that secrete their own insulin. As a result, the pancreas does not produce enough insulin. Due to the lack of insulin secretion, patients need to rely on exogenous insulin supplements to maintain life.
②II型糖尿病是成人发病型糖尿病,多在35-40岁之后发病,占糖尿病患者90%以上。患者体内产生胰岛素的能力并非完全丧失,有的患者体内胰岛素甚至产生过多,但胰岛素的作用效果却大打折扣,因此患者体内的胰岛素是一种相对缺乏。②Type II diabetes is adult-onset diabetes, which usually occurs after the age of 35-40, accounting for more than 90% of diabetic patients. The ability to produce insulin in the patient's body is not completely lost, and some patients even produce too much insulin in the body, but the effect of insulin is greatly reduced, so the insulin in the patient's body is relatively deficient.
II型糖尿病有更强的遗传性和环境因素,并呈显著的异质性,其典型病例可出现多尿、多饮、多食、消瘦等表现,即“三多一少”症状,糖尿病一旦控制不好会引发并发症,导致肾、眼、足等部位的衰竭病变,且无法治愈。Type II diabetes has stronger genetic and environmental factors, and shows significant heterogeneity. Its typical cases may show symptoms such as polyuria, polydipsia, polyphagia, and weight loss, that is, "three more and one less". Poor control will lead to complications, leading to failure of the kidneys, eyes, feet and other parts of the disease, and can not be cured.
如今,最常用的治疗手段为服用二甲双胍等降糖药物,治标不治本,只能降血糖而无法治血糖,长期服用不仅会给患者的身体带来负担,而且还容易使患者身体出现抗药性。Nowadays, the most commonly used treatment method is to take hypoglycemic drugs such as metformin, which treats the symptoms but not the root cause. It can only lower blood sugar but not treat blood sugar. Long-term use will not only bring burden to the patient's body, but also easily cause drug resistance in the patient's body.
中医治疗糖尿病注重整体调控,在改善症状等方面明显优于西医。适合于非胰岛素依赖型糖尿病(即II型糖尿病),因此现需要研发治疗糖尿病的中药组合物。TCM treatment of diabetes pays attention to overall regulation, and is obviously superior to Western medicine in improving symptoms and other aspects. It is suitable for non-insulin-dependent diabetes mellitus (namely type II diabetes mellitus), so it is necessary to develop a traditional Chinese medicine composition for treating diabetes mellitus.
发明内容Contents of the invention
本发明针对现有西药治疗糖尿病的不足,提供一种治疗糖尿病的中药组合物。The invention aims at the deficiency of existing western medicine in treating diabetes, and provides a traditional Chinese medicine composition for treating diabetes.
本发明解决上述技术问题的技术方案如下:一种治疗糖尿病的中药组合物,其原料组成及配比如下:The technical solution of the present invention to solve the above-mentioned technical problems is as follows: a kind of Chinese medicine composition for treating diabetes, its raw material composition and proportioning are as follows:
山萸肉28~32重量份;人参须36~42重量份;生地28~32重量份;黄精28~32重量份;黄芪18~22重量份;白芍18~22重量份;枸杞子36~42重量份;知母28~32重量份;元参28~32重量份;黄连36~42重量份;乌梅28~32重量份;番石榴皮36~42重量份;牡蛎28~32重量份;银柴胡18~22重量份;胡黄连28~32重量份;丹参28~32重量份;鬼箭羽36~42重量份;芦荟14~16重量份;虎杖28~32重量份。28-32 parts by weight of cornus; 36-42 parts by weight of ginseng root; 28-32 parts by weight of raw land; 28-32 parts by weight of sealwort; 42 parts by weight; Anemarrhena 28-32 parts by weight; Yuanshen 28-32 parts by weight; Coptidis 36-42 parts by weight; Black plum 28-32 parts by weight; Guava peel 36-42 parts by weight; Silver Bupleurum 18-22 parts by weight; Coptis chinensis 28-32 parts by weight; Salvia miltiorrhiza 28-32 parts by weight; Guijianyu 36-42 parts by weight; Aloe vera 14-16 parts by weight; Polygonum cuspidatum 28-32 parts by weight.
优选的,所述疗糖尿病的中药组合物的原料组成及配比如下:山萸肉30重量份;人参须40重量份;生地30重量份;黄精30重量份;黄芪20重量份;白芍20重量份;枸杞子40重量份;知母30重量份;元参30重量份;黄连40重量份;乌梅30重量份;番石榴皮40重量份;牡蛎30重量份;银柴胡20重量份;胡黄连30重量份;丹参30重量份;鬼箭羽40重量份;芦荟15重量份;虎杖30重量份。Preferably, the raw material composition and proportioning ratio of the traditional Chinese medicine composition for treating diabetes are as follows: 30 parts by weight of cornus; 40 parts by weight of ginseng root; 30 parts by weight of rhizoma rhizome; Parts by weight: 40 parts by weight of medlar; 30 parts by weight of Anemarrhena; 30 parts by weight of Yuanshen; 40 parts by weight of Coptidis; 30 parts by weight of black plum; 30 parts by weight of berberine; 30 parts by weight of salvia miltiorrhiza; 40 parts by weight of ghost arrow feather; 15 parts by weight of aloe; 30 parts by weight of knotweed.
进一步,所述中药组合物通过添加或不添加辅料制成胶囊剂、颗粒剂、丸剂、或汤剂。Further, the traditional Chinese medicine composition is prepared into capsules, granules, pills, or decoctions by adding or not adding auxiliary materials.
所述辅料为各种药学上常用的辅料和/或赋形剂,包括(但不限于)糖类(如乳糖、葡萄糖和蔗糖),淀粉(如玉米淀粉和土豆淀粉),纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素和甲基纤维素),黄蓍胶粉末,麦芽,明胶,滑石,固体润滑剂(如硬脂酸和硬脂酸镁),硫酸钙,植物油,如花生油、棉籽油、芝麻油、橄榄油、玉米油和可可油,多元醇(如丙二醇、甘油、山梨糖醇、甘露糖醇和聚乙二醇),海藻酸,乳化剂(如Tween),润湿剂(如月桂基硫酸钠),着色剂,调味剂,压片剂、稳定剂,抗氧化剂,防腐剂,无热原水,等渗盐溶液和磷酸盐缓冲液等。辅料可根据需要提高配方的稳定性、活性及生物有效性等,或在口服的情况下产生可接受的口感或气味。The adjuvant is a variety of commonly used pharmaceutical adjuvants and/or excipients, including (but not limited to) sugars (such as lactose, glucose and sucrose), starches (such as corn starch and potato starch), cellulose and derivatives thereof substances (such as sodium carboxymethylcellulose, ethylcellulose, and methylcellulose), tragacanth powder, malt, gelatin, talc, solid lubricants (such as stearic acid and magnesium stearate), calcium sulfate, Vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and cocoa butter, polyols (such as propylene glycol, glycerin, sorbitol, mannitol, and polyethylene glycol), alginic acid, emulsifiers (such as Tween), Wetting agent (such as sodium lauryl sulfate), coloring agent, flavoring agent, tableting agent, stabilizer, antioxidant, preservative, pyrogen-free water, isotonic saline solution and phosphate buffer, etc. Excipients can improve the stability, activity and bioavailability of the formula as needed, or produce acceptable taste or smell when taken orally.
本发明的中药组合物中,方中山萸肉补益肝肾,固涩精气;人参须大补元气,生津止渴;生地养阴清热,生津润燥。三药相配,共凑养阴益气、清热生津之效,共为君药。臣以黄精、黄芪滋肾润肺,健脾益气;白芍、枸杞补肝肾阴;知母、元参、黄连清泄肺胃燥热而滋阴,以增君药之功。乌梅敛阴生津止渴;番石榴皮、牡蛎收敛固涩;银柴胡、胡黄连入阴分清虚热;丹参、鬼箭羽活血祛瘀;芦荟、虎杖泻下通便,共为佐药。In the traditional Chinese medicine composition of the present invention, the cornus in the prescription nourishes the liver and kidneys, consolidates astringent essence; The combination of the three medicines has the effects of nourishing yin and replenishing qi, clearing away heat and promoting body fluid, and is a king medicine. The minister uses sealwort and astragalus to nourish the kidneys and lungs, strengthen the spleen and replenish qi; white peony root and wolfberry to nourish the liver and kidney yin; Anemarrhena, root ginseng, and coptis to clear away dryness and heat in the lungs and stomach and nourish yin to enhance the power of the king's medicine. Black plum astringes yin to promote fluid and quench thirst; guava peel and oyster astringe and solidify astringent; Yin Bupleurum and Huhuanglian enter yin to clear deficiency and heat; salvia miltiorrhiza and ghost arrow feather promote blood circulation and remove blood stasis; aloe vera and polygonum cuspidatum purify laxative and are adjuvant medicines.
本发明第二方面公开了前述治疗糖尿病的中药组合物的制备方法,为煎煮法,包括以下步骤:The second aspect of the present invention discloses a preparation method of the aforementioned traditional Chinese medicine composition for treating diabetes, which is a decocting method, comprising the following steps:
1)浸泡:按照中药组合物的配方,将原料放入8~10倍量冷水中浸泡20~40分钟;1) Soaking: according to the formula of the traditional Chinese medicine composition, put the raw materials into 8 to 10 times the amount of cold water and soak for 20 to 40 minutes;
2)煎煮:将泡好的药材大火煎开,转小火煎40~60分钟后,过滤分离获得药渣和滤液;2) Decoction: decoct the soaked medicinal materials on high heat, turn to low heat and decoct for 40-60 minutes, then filter and separate to obtain medicinal residues and filtrate;
3)二次煎煮:向前一步骤的药渣中再次加4~6倍量的水,大火煎开后转小火煎30~40分钟,过滤取滤液;3) Second decoction: Add 4 to 6 times the amount of water to the dregs of the previous step, decoct on high heat, turn to low heat and decoct for 30 to 40 minutes, filter to get the filtrate;
4)合并步骤2)和步骤3)的滤液,低温蒸发浓缩至相对密度为1.05~1.15,获得中药组合物的汤剂。4) Combine the filtrates of step 2) and step 3), evaporate and concentrate at low temperature to a relative density of 1.05-1.15, and obtain a decoction of the traditional Chinese medicine composition.
本发明还公开了另一种治疗糖尿病的中药组合物的制备方法,为水提醇沉法,包括以下步骤:The present invention also discloses another preparation method of a traditional Chinese medicine composition for treating diabetes, which is a water extraction and alcohol precipitation method, comprising the following steps:
①煎煮:按照中药组合物的配方,向原料中加入8~10倍量的水,加热煎煮1~2小时;固液分离后,加4~6倍量的水,加热煎煮1~1.5小时,合并两次煎煮的滤液;①Decoction: According to the formula of the traditional Chinese medicine composition, add 8 to 10 times the amount of water to the raw materials, heat and decoct for 1 to 2 hours; after solid-liquid separation, add 4 to 6 times the amount of water, heat and decoct for 1 to 2 hours For 1.5 hours, combine the filtrates of the two decoctions;
②将滤液低温蒸发浓缩至相对密度为1.15~1.2,搅拌条件下,缓缓加入2倍量的95%v/v乙醇溶液,搅拌18~25分钟,冷沉36~60小时,倾出上清液,滤过;② Concentrate the filtrate by low-temperature evaporation to a relative density of 1.15-1.2. Under stirring conditions, slowly add 2 times the amount of 95% v/v ethanol solution, stir for 18-25 minutes, cool down for 36-60 hours, and pour out the supernatant liquid, filtered;
③蒸馏回收乙醇,再继续蒸发浓缩至相对密度为1.25~1.35,放置20~28小时使沉淀完全,滤过,滤液在低温蒸发至稠膏状;③Recover ethanol by distillation, continue to evaporate and concentrate to a relative density of 1.25-1.35, place it for 20-28 hours to complete the precipitation, filter, and evaporate the filtrate to a thick paste at low temperature;
④向前一步骤的稠膏中加入辅料制成软材,混匀,制成颗粒,干燥,获得中药组合物的颗粒剂。④ Add auxiliary materials to the thick paste in the previous step to make a soft material, mix well, make granules, and dry to obtain granules of the traditional Chinese medicine composition.
本发明最后一方面公开了前述中药组合物在制备治疗Ⅱ型糖尿病药物中的应用。The last aspect of the present invention discloses the application of the aforementioned traditional Chinese medicine composition in the preparation of medicaments for treating type Ⅱ diabetes.
本发明的有益效果是:本发明的中药组合物益气养阴,清热生津。用于II型糖尿病燥热伤津兼气阴两虚证,症见口渴多饮,尿量频多,消谷善饥,形体渐瘦,倦怠乏力,自汗盗汗,五心烦热,尿浊,便秘等。The beneficial effects of the present invention are: the traditional Chinese medicine composition of the present invention nourishes qi and nourishes yin, clears away heat and promotes body fluid. It is used for type II diabetes with dryness, heat, body fluid and deficiency of both qi and yin. Symptoms include excessive thirst, frequent urination, elimination of grains and good hunger, gradual thinning, fatigue, spontaneous sweating, night sweats, dysphoria and fever, and turbid urine. Constipation etc.
具体实施方式Detailed ways
以下对本发明的原理和特征进行描述,所举实例只用于解释本发明,并非用于限定本发明的范围。The principles and features of the present invention are described below, and the examples given are only used to explain the present invention, and are not intended to limit the scope of the present invention.
实施例1中药组合物汤剂的制备The preparation of embodiment 1 Chinese medicine composition decoction
1.中药组合物配方1. Traditional Chinese medicine composition formula
山萸肉30g,人参须40g,生地30g;黄精30g,黄芪20g,白芍20g,枸杞子40g,知母30g,元参30g,黄连40g;乌梅30g,番石榴皮40g,牡蛎30g,银柴胡20g,胡黄连30g,丹参30g,鬼箭羽40g,芦荟15g,虎杖30g。30g of cornus, 40g of ginseng, 30g of raw land; 30g of sealwort, 20g of astragalus, 20g of white peony, 40g of medlar, 30g of anemarrhena, 30g of ginseng, 40g of coptis; 30g of black plum, 40g of guava skin, 30g of oyster, silver wood Hu 20g, Hu Huanglian 30g, Danshen 30g, ghost arrow feather 40g, aloe vera 15g, knotweed 30g.
2.制备方法2. Preparation method
1)将上述药材置于钢蒸锅内,用冷水量约为药材的8倍量,浸泡30分钟;1) Put the above-mentioned medicinal materials in a steel steamer, use about 8 times the amount of cold water as the medicinal materials, and soak for 30 minutes;
2)将浸泡好的药材用武火煎开,转温火煎煮50分钟,滤出药液;2) Decoct the soaked medicinal materials with strong fire, turn to warm fire and cook for 50 minutes, and filter out the medicinal liquid;
3)滤出药液后,再次加入5倍量凉水煎开,转温火煎煮40分钟,滤出药液;3) After filtering out the medicinal liquid, add 5 times the amount of cold water to boil again, turn to warm fire and boil for 40 minutes, and filter out the medicinal liquid;
4)将上述步骤2)与步骤3)的药液合并、混匀、滤过,滤液低温蒸发浓缩至相对密度为1.1的汤剂。4) Merge, mix and filter the medicinal solution in the above step 2) and step 3), and concentrate the filtrate by low-temperature evaporation to a decoction with a relative density of 1.1.
实施例2中药组合物颗粒的制备The preparation of embodiment 2 Chinese medicine composition granules
1.中药组合物配方1. Traditional Chinese medicine composition formula
山萸肉28g,人参须42g,生地28g;黄精32g,黄芪22g,白芍18g,枸杞子36g,知母32g,元参28g,黄连36g;乌梅28g,番石榴皮42g,牡蛎32g,银柴胡18g,胡黄连28g,丹参28g,鬼箭羽42g,芦荟14g,虎杖32g。28g of cornus, 42g of ginseng, 28g of raw land; 32g of sealwort, 22g of astragalus, 18g of white peony, 36g of medlar, 32g of anemarrhena, 28g of ginseng, 36g of coptis; 28g of black plum, 42g of guava skin, 32g of oyster, silver chai Hu 18g, Hu Huanglian 28g, Salvia miltiorrhiza 28g, ghost arrow feather 42g, aloe vera 14g, knotweed 32g.
2.制备方法2. Preparation method
①将上述药材,第一次加水约10倍量的水,加热煎煮1.5小时;第二次加水约4倍量的水,加热煎煮1.5小时,合并滤液,滤过。① Add about 10 times the amount of water to the above medicinal materials for the first time, heat and decoct for 1.5 hours; add about 4 times the amount of water for the second time, heat and decoct for 1.5 hours, combine the filtrates, and filter.
②滤液低温蒸发浓缩至相对密度为1.15,充分搅拌下,缓缓加入2倍量的95%乙醇,搅拌20分钟,冷沉48小时,倾出上清液,滤过。②Concentrate the filtrate by low-temperature evaporation to a relative density of 1.15. With full stirring, slowly add 2 times the amount of 95% ethanol, stir for 20 minutes, cool down for 48 hours, pour out the supernatant, and filter.
③蒸馏回收乙醇,再继续蒸发浓缩至相对密度为1.3,冷处放置24小时,使沉淀完全,滤过,滤液在低温蒸发至稠膏状,备用。③ Recover ethanol by distillation, continue to evaporate and concentrate to a relative density of 1.3, place in a cold place for 24 hours to make the precipitation complete, filter, evaporate the filtrate to a thick paste at low temperature, and set aside.
④将稠膏放置在容器内,加入糊精(糊精与稠膏质量比为1:2)及体积浓度为70%的乙醇溶液制成软材,混匀,制成颗粒,干燥,即得中药组合物颗粒剂。④ Put the thick paste in a container, add dextrin (the mass ratio of dextrin to thick paste is 1:2) and ethanol solution with a volume concentration of 70% to make a soft material, mix well, make granules, and dry to obtain Traditional Chinese medicine composition granules.
实施例3中药组合物胶囊的制备The preparation of embodiment 3 Chinese medicine composition capsules
1.中药组合物配方1. Traditional Chinese medicine composition formula
山萸肉32g,人参须36g,生地32g;黄精28g,黄芪18g,白芍22g,枸杞子42g,知母28g,元参32g,黄连42g;乌梅32g,番石榴皮36g,牡蛎28g,银柴胡22g,胡黄连32g,丹参32g,鬼箭羽36g,芦荟16g,虎杖28g。32g of cornus, 36g of ginseng, 32g of raw land; 28g of sealwort, 18g of astragalus, 22g of white peony, 42g of medlar, 28g of anemarrhena, 32g of ginseng, 42g of coptis; 32g of black plum, 36g of guava skin, 28g of oyster, silver wood Hu 22g, Hu Huanglian 32g, Salvia 32g, Guijian Yu 36g, Aloe Vera 16g, Polygonum cuspidatum 28g.
2.制备方法2. Preparation method
①将上述药材干燥,混匀,粉粹成细粉,均应通过六号筛。①Dry the above medicinal materials, mix them evenly, and grind them into fine powder, all of which should pass through a No. 6 sieve.
②将上述药材粉末,干燥情况下装入1号胶囊,每个重量0.5克。②Put the above-mentioned medicinal material powder into No. 1 capsule under dry conditions, each weighing 0.5 grams.
实施例4中药组合物治疗糖尿病的动物试验Embodiment 4 Chinese medicine composition treats the animal test of diabetes
1.Ⅱ型糖尿病动物模型的构建1. Construction of animal model of type Ⅱ diabetes mellitus
选择健康7周龄雄性SD大鼠给予高脂饮食(高脂饮食所采用的高脂高糖饲料配方为:猪油15%,蔗糖20%,胆固醇5%,普通鼠饲料60%,均为质量百分含量)8周后,腹腔注射链脲佐菌素(0.5%链脲佐菌素30mg/kg,0.1mmol/L柠檬酸缓冲液,pH4.4),注射7d后,成功制备Ⅱ型糖尿病大鼠50只。Select healthy 7-week-old male SD rats to give a high-fat diet (the high-fat and high-sugar feed formula adopted by the high-fat diet is: lard 15%, sucrose 20%, cholesterol 5%, common mouse feed 60%, all are quality percentage content) after 8 weeks, intraperitoneal injection of streptozotocin (0.5% streptozotocin 30mg/kg, 0.1mmol/L citrate buffer, pH4.4), after 7 days of injection, type Ⅱ diabetes mellitus was successfully prepared 50 rats.
2.实验方法及结果2. Experimental methods and results
以未处理的10只SD大鼠作为空白对照组;将构建成功的50只Ⅱ型糖尿病大鼠随机选择10只作为模型对照组,剩余的模型大鼠随机平均分为两组,分别为中药组合物组(本发明的中药组合物),及优降糖组(格列本脲片,购自广东三才医药集团有限公司)。中药组每日灌胃给药1次(实施例1制备的中药组合物汤剂10ml/kg),优降糖组每日用药(7.8mg/kg),模型对照组和空白对照组分别给予等容量的生理盐水(每100g给予1mL),连续用药30d。分别于药后第15天、30天,禁食12h,测血糖1次,结果见表1。10 untreated SD rats were used as the blank control group; 10 of the 50 successfully constructed type II diabetic rats were randomly selected as the model control group, and the remaining model rats were randomly and equally divided into two groups. Object group (traditional Chinese medicine composition of the present invention), and glyburide group (glibenclamide tablets, purchased from Guangdong Sancai Pharmaceutical Group Co., Ltd.). The Chinese medicine group was intragastrically administered once a day (10ml/kg of the Chinese medicine composition decoction prepared in Example 1), the glyburbide group was administered daily (7.8mg/kg), and the model control group and the blank control group were administered respectively. Volume of normal saline (administered 1mL per 100g), continuous medication for 30d. On the 15th day and 30th day after taking the medicine, respectively, they fasted for 12 hours and measured their blood sugar once. The results are shown in Table 1.
表1中药组合物对小鼠血糖的影响Table 1 The influence of traditional Chinese medicine composition on mouse blood sugar
与模型对照组比较,*P<0.05,**P<0.01。Compared with the model control group, *P<0.05, **P<0.01.
由上表1可知,本发明的中药组合物与模型对照组相比,可显著降低链脲佐菌素诱发的Ⅱ型糖尿病大鼠的血糖,对糖尿病治疗有显著效果。It can be seen from the above table 1 that, compared with the model control group, the traditional Chinese medicine composition of the present invention can significantly reduce the blood sugar of streptozotocin-induced type II diabetic rats, and has a significant effect on the treatment of diabetes.
实施例5中药组合物临床治疗糖尿病的效果The effect of embodiment 5 Chinese medicine composition clinical treatment diabetes
1.病例选择:1. Case selection:
病例按WHO糖尿病诊断标准选择,均为II糖尿病患者,并符合《中药新药治疗消渴病(糖尿病)的临床研究指导原则》中气阴两虚症辩证标准。The cases were selected according to the WHO diabetes diagnostic criteria, all of them were II diabetic patients, and they met the dialectical criteria of deficiency of both qi and yin in the "Guiding Principles for Clinical Research of New Chinese Medicines for Diabetes (Diabetes)".
共收治患者300例,随机分为治疗组和对照组:治疗组120例,其中男60例,女60例,年龄在38~65岁,病程3~15年;病情程度:轻度23例,中度64例,重度33例。对照组120例,其中男63例,女57例,年龄38~65岁,病程3~15年;病情程度:轻度24例,中度68例,重度28例。A total of 300 patients were admitted and randomly divided into a treatment group and a control group: 120 cases in the treatment group, including 60 males and 60 females, aged 38-65 years, with a course of 3-15 years; the severity of the disease: 23 cases were mild, Moderate in 64 cases, severe in 33 cases. The control group consisted of 120 cases, including 63 males and 57 females, aged 38 to 65 years, with a course of disease of 3 to 15 years; disease severity: 24 cases were mild, 68 cases were moderate, and 28 cases were severe.
2.治疗方法:2. Treatment method:
两组均按要求控制饮食。治疗组口服实施例1的中药组合物汤剂200-250ml,每日2次,中、晚餐前30min饮用;对照组口服消渴丸(广州中一药业有限公司),每次8粒,每日3次,早、中、晚餐前30min温开水服送。两组用药疗程均为60天。Both groups controlled diet as required. The treatment group oral Chinese medicine composition decoction 200-250ml of embodiment 1, every day 2 times, drink 30min before lunch and dinner; Control group oral Xiaoke pill (Guangzhou Zhongyi Pharmaceutical Co., Ltd.), each 8, each 3 times a day, take with warm water 30 minutes before breakfast, lunch and dinner. The course of treatment for both groups was 60 days.
3.疗效制定标准3. Formulate standards for curative effect
参照卫生部制定的《中药新药治疗消渴病(糖尿病)的临床研究指导原则》中疗效判定标准。Refer to the curative effect judging criteria in the "Guiding Principles for Clinical Research of New Drugs of Traditional Chinese Medicine in the Treatment of Diabetes (Diabetes)" formulated by the Ministry of Health.
4.治疗结果:4. Treatment results:
治疗效果的结果见下表2。The results of the treatment effects are shown in Table 2 below.
表2中药组合物治疗效果Table 2 Chinese medicine composition therapeutic effect
可见本发明中药组合物的效果接近现有糖尿病治疗药物的疗效。对改善口渴多饮、消谷善饥、多尿、倦怠乏力、自汗盗汗,五心烦热、尿浊,便秘等临床的总有效率,治疗组优于对照组,揭示所述中药组合物的胶囊的疗效优于对照组。It can be seen that the effect of the traditional Chinese medicine composition of the present invention is close to the curative effect of the existing diabetes treatment drugs. For improving the clinical total effective rate of thirst and polydipsia, eliminating gluten and hunger, polyuria, lassitude and fatigue, spontaneous sweating and night sweating, dysphoria and fever, turbid urine, constipation, etc., the treatment group is better than the control group, revealing that the traditional Chinese medicine composition The curative effect of the capsule is better than that of the control group.
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。The above descriptions are only preferred embodiments of the present invention, and are not intended to limit the present invention. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention shall be included in the protection of the present invention. within range.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510243922.XA CN104815166B (en) | 2015-05-13 | 2015-05-13 | A kind of Chinese medicine composition for treating diabetes and its preparation and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510243922.XA CN104815166B (en) | 2015-05-13 | 2015-05-13 | A kind of Chinese medicine composition for treating diabetes and its preparation and application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104815166A CN104815166A (en) | 2015-08-05 |
CN104815166B true CN104815166B (en) | 2018-01-12 |
Family
ID=53725810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510243922.XA Active CN104815166B (en) | 2015-05-13 | 2015-05-13 | A kind of Chinese medicine composition for treating diabetes and its preparation and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104815166B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106511506A (en) * | 2017-01-18 | 2017-03-22 | 中国科学院长春应用化学研究所 | Traditional Chinese medicine composition for treating diabetes, preparation method and application thereof |
CN108324852A (en) * | 2018-04-19 | 2018-07-27 | 合肥市风达农业有限责任公司 | A kind of Chinese medicine composition for treating diabetes |
CN108403824A (en) * | 2018-05-30 | 2018-08-17 | 江西九华药业有限公司 | A kind of combined traditional Chinese medicine cream for treating hemorrhoid |
CN108578605A (en) * | 2018-07-18 | 2018-09-28 | 合肥华盖生物科技有限公司 | A kind of Chinese medicine composition for treating diabetes |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1879783A (en) * | 2006-05-18 | 2006-12-20 | 张将勇 | A medicine for treating diabetes |
CN102274447A (en) * | 2011-08-27 | 2011-12-14 | 赵国辉 | Medicinal composition for treating diabetes |
-
2015
- 2015-05-13 CN CN201510243922.XA patent/CN104815166B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1879783A (en) * | 2006-05-18 | 2006-12-20 | 张将勇 | A medicine for treating diabetes |
CN102274447A (en) * | 2011-08-27 | 2011-12-14 | 赵国辉 | Medicinal composition for treating diabetes |
Non-Patent Citations (1)
Title |
---|
补肾阳法治疗糖尿病;徐丹慧等;《河南中医》;19981020(第05期);314- * |
Also Published As
Publication number | Publication date |
---|---|
CN104815166A (en) | 2015-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103083531B (en) | Drug for treating diabetes | |
CN101947284B (en) | Traditional Chinese medicinal composition for treating diabetes and preparation method thereof | |
CN101524471A (en) | Pharmaceutical composition for treating diabetes and preparation method thereof | |
CN101524469B (en) | A kind of traditional Chinese medicine compound preparation for treating congestive heart failure and preparation method thereof | |
CN104815166B (en) | A kind of Chinese medicine composition for treating diabetes and its preparation and application | |
CN103933346B (en) | A kind of compound for reducing blood suger and preparation method thereof | |
CN104083640B (en) | Traditional Chinese medicinal composition for treating diabetes mellitus and preparation method thereof | |
CN105267559B (en) | A kind of drug and preparation method thereof for treating diabete peripheral herve pathology | |
CN100509025C (en) | A medicine for treating diabetes | |
CN102188522B (en) | Traditional Chinese medicine composition for treating constipation | |
CN115252753A (en) | Traditional Chinese medicine composition for treating insomnia and its application | |
CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
CN112741862A (en) | Compound medicine of coptis, astragalus, notoginseng and rehmannia for preventing and treating diabetes and its complication | |
CN105902897A (en) | Pharmaceutical preparation for treating pancreatic cancer and application thereof | |
CN100558377C (en) | Traditional Chinese medicine composition for treating renal insufficiency and preparation method thereof | |
CN104524359B (en) | A kind of Chinese medicine composition, its preparation method and application | |
CN104721595B (en) | A kind of Chinese medicine composition treating hyperlipidaemia | |
CN117045764B (en) | Traditional Chinese medicine composition for treating type II diabetes and preparation method thereof | |
CN100387270C (en) | A kind of traditional Chinese medicine preparation for treating and preventing diabetes and its vascular disease | |
CN108392583A (en) | A kind of Chinese medicine preparation for treating diabetic nephropathy | |
CN101947299A (en) | Medicinal composition for treating coronary heart disease | |
CN117899159A (en) | Medicine for treating bone marrow suppression after chemotherapy and preparation method thereof | |
CN103393937B (en) | A kind of pharmaceutical composition and its production and use | |
CN104547415A (en) | Application of traditional Chinese medicinal composition for preparing medicine for treating diabetes | |
CN120346261A (en) | Traditional Chinese medicine composition for treating hypertension and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221031 Address after: 2nd Floor, Building 1, Standard Factory Building, Tongmu Town Industrial Concentration Zone, Jinxiu Yao Autonomous County, Laibin City, Guangxi Zhuang Autonomous Region 546100 "Business Site (1) Guchi Village, Tongmu Town, Jinxiu County" Patentee after: Guangxi Jinxiu huicui materia medica industry Co.,Ltd. Address before: 510000 2414-2416 of the main building 371, five mountain road, Tianhe District, Guangzhou, Guangdong. Patentee before: GUANGDONG GAOHANG INTELLECTUAL PROPERTY OPERATION Co.,Ltd. Effective date of registration: 20221031 Address after: 510000 2414-2416 of the main building 371, five mountain road, Tianhe District, Guangzhou, Guangdong. Patentee after: GUANGDONG GAOHANG INTELLECTUAL PROPERTY OPERATION Co.,Ltd. Address before: 264000 No. 186 Hongqi Middle Road, Zhifu District, Shandong, Yantai Patentee before: LUDONG University |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: No.268, wutong Avenue, Tongmu Town, Laibin City, Guangxi Zhuang Autonomous Region "Business location: (I) Guchi Village Committee, Guchi Village, Tongmu Town, Jinxiu County." Patentee after: Guangxi Hongyao Biotechnology Co.,Ltd. Country or region after: China Address before: The second floor of standard factory building 1 in Tongmu Town, Jinxiu Yao Autonomous County, Laibin City, Guangxi Zhuang Autonomous Region Patentee before: Guangxi Jinxiu huicui materia medica industry Co.,Ltd. Country or region before: China |